Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penehyclidine vs droperidol for prevention of postoperative nausea and vomiting after thyroid surgery under general anesthesia
ChiCTR2500107170Phase 4Not yet recruiting
- Sponsor
- Weifang People's Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of penehyclidine in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Weifang People's Hospital. Primary endpoint: Incidence of PONV within 24 hours after surgery. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
penehyclidine
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2500107170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107170.